US-listed shares of Theratechnologies falls as FDA extends drug review

Theratechnologies

23/01/2024 13:39

** U.S.-listed shares of Canadian drug maker
Theratechnologies  TH.TO   THTX.O  fall 25.4% to $1.38 premarket
    ** THTX says the U.S. FDA has extended its review beyond the
target date of Jan 22, on a more concentrated formulation of
co's drug Egrifta SV
    ** Egrifta SV is approved for the reduction of excess
abdominal fat in HIV-infected adult patients with lipodystrophy
    ** Lipodystrophy affects the redistribution of fat that
includes the accumulation and loss of fat in certain parts of
the human body
     ** The drug is also being tested as a potential treatment
for a fatty liver disease called metabolic
dysfunction-associated steatohepatitis (MASH, formerly known as
nonalcoholic steatohepatitis or NASH)
    ** Up to Monday's close, stock has fallen 53.3% in the last
12 months 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))